SG3 Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

SG3 Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,000	Closed	-$639K	–	505
2022 Q2	$639K	Buy	+20,000	New	+$585K	0.08%	181
2022 Q1	–	Sell	-15,000	Closed	-$439K	–	1491
2021 Q4	$439K	Buy	+15,000	New	+$465K	0.01%	661
2021 Q1	–	Sell	-10,000	Closed	-$433K	–	1567
2020 Q4	$433K	Sell	10,000 -92,900	-90%	-$4.58M	0.01%	760
2020 Q3	$5.67M	Buy	+102,900	New	+$6.54M	0.21%	116

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SG3 Management's GBT Position: Q1 2022 in Review

SG3 Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 5,000 shares — an estimated $146K sold.

SG3 Management first reported a position in GBT in Q4 2020 and held it in 2 quarters. The position peaked at $346K in Q4 2020. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

SG3 Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 5,000 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $146K.
SG3 Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
SG3 Management's Global Blood Therapeutics, Inc. position peaked at $346K in Q4 2020.
204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.